New Anticancer Drugs: Reliably Assessing “Value” While Addressing High Prices
Countries face challenges in paying for new drugs. High prices are driven in part by exploding drug development costs, which, in turn, are driven by essential but excessive regulation. Burdensome regulation also delays drug development, and this can translate into thousands of life-years lost. We ne...
I tiakina i:
| Ngā kaituhi matua: | , , , , , , , , , , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
MDPI AG
2024-04-01
|
| Rangatū: | Current Oncology |
| Ngā marau: | |
| Urunga tuihono: | https://www.mdpi.com/1718-7729/31/5/184 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|